Alpha Interferon Inhibits Avian Influenza Viral Replication
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for preventing or reducing antigenic drift and reassortment of viruses, particularly in the case of highly pathogenic avian influenza strains like H7N9, which can lead to severe human infections and are resistant to existing treatments.
Innovation Solution
Administering α-interferon to host animals exposed to or infected with avian influenza viruses, such as H7N9, to inhibit viral multiplication and reduce the severity of symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antiviral drugs (neuraminidase inhibitors) are used to treat influenza, then viral replication is inhibited, but drug-resistant mutations emerge rapidly
Solution Approach 1:
The patent uses α-interferon as an intermediary substance that activates the host's innate immune system to combat the virus. Instead of directly targeting the virus with neuraminidase inhibitors, the treatment works through the host's cellular defense mechanisms, thereby avoiding direct selection pressure that leads to drug-resistant mutations.
Solution Approach 2:
The patent changes the therapeutic parameter from direct viral enzyme inhibition (neuraminidase inhibitors) to host immune system modulation (α-interferon treatment). This parameter change shifts the mechanism of action from targeting viral proteins to enhancing host cellular responses, thereby avoiding viral resistance to specific drug molecules.
2Stability of the object's composition
If influenza viruses are allowed to evolve naturally, then antigenic drift and reassortment occur continuously, but universal vaccine development is hindered
Solution Approach 1:
The patent applies α-interferon treatment early in the infection process to prevent viral replication and genetic reassortment before they can occur. By acting preliminarily to block viral multiplication, the treatment prevents the conditions necessary for antigenic drift and reassortment from developing.
Solution Approach 2:
The patent employs α-interferon to create a preliminary protective state in host cells that makes them resistant to viral infection and replication. This preliminary anti-action prevents the virus from establishing infection and undergoing genetic changes, thereby maintaining viral genetic stability in the host population.
3Productivity
If vaccination programs are implemented quickly during a pandemic, then herd immunity is achieved, but the lengthy development time of conventional vaccines limits effectiveness
Solution Approach 1:
The patent replaces the mechanical manufacturing and distribution system of conventional vaccines with a biological therapy system (α-interferon administration). This substitution eliminates the lengthy vaccine development, production, and distribution timeline, allowing immediate treatment deployment during outbreaks.
Solution Approach 2:
The patent uses a readily available, off-the-shelf therapeutic agent (α-interferon) that does not require pandemic-specific development. This approach uses existing medical resources that can be deployed immediately without the time-consuming process of developing new pandemic-specific vaccines.
4Difficulty of detecting and measuring
If monitoring of poultry for influenza symptoms is used to detect outbreaks, then early warning is provided, but A(H7N9) produces few symptoms in poultry making detection difficult
Solution Approach 1:
The patent enables the poultry population to self-protect against influenza infection through α-interferon treatment. By enhancing their own immune defenses, poultry can resist viral infection even when asymptomatic, thereby eliminating the need to detect symptoms for outbreak prevention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
α-Interferon effectively reduces tissue damage and viral replication in both wild-type and neuraminidase-resistant H7N9 strains, providing a novel approach to combat newly uncovered genetically re-assorted and drug-resistant viruses.
Implementation Method 1
α-interferon effectively reduces tissue damage and viral replication in both wild-type and neuraminidase-resistant H7N9 strains
Data Source
AI summary
This disclosures relates to methods of preventing or reducing antigenic drift, viral reassortment and symptoms of wild-type and mutant influenza viruses in a host animal by determining if a host animal has been exposed to or infected by an avian influenza virus, and administering to the exposed host animal α-interferon.